Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sustained-release flucytosine pharmacokinetics in early cryptococcal disease
ISRCTN18180872Phase 2Recruiting
- Sponsor
- Wits Health Consortium
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flucytosine and fluconazole in cryptococcosis and human immunodeficiency virus infection (HIV), sponsored by Wits Health Consortium. Primary endpoints: AUC(0-24h) for flucytosine and possibly 5-fluorouracil, Plasma pharmacokinetics of flucytosine and 5-fluorouracil and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
flucytosinefluconazole
03
Conditions
cryptococcosishuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN18180872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18180872.